Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 271-279

  Knez, Lea ^a   Sodja, Eva ^a   Kern, Izidor ^a   Košnik, Mitja ^a   Cufer, Tanja ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

Author keywords

ERCC1; MDR1; MRP; Multidrug resistance associated proteins; MVP; Predictive factor; Small cell lung cancer; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; GENE EXPRESSION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; UPREGULATION;

BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG THERAPY; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; P-GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 79955466333     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.014     Document Type: Review

References (47)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008. Cancer incidence and mortality worldwide: IARC cancer base no. 10 2010, International Agency for Research on Cancer, Lyon.
2. Primic-Žakelj M., Zadnik V., Žagar T., Zakotnik B., Anderluh F., Bešić N., et al. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia 2009, Institute of Oncology Ljubljana, Ljubljana.
3. Foster N.R., Mandrekar S.J., Schild S.E., Nelson G.D., Rowland K.M., Deming R.L., et al. Prognostic factors differ by tumor stage for small cell lung cancer. Cancer 2009, 115:2721-2731.
4. Hurwitz J.L., McCoy F., Scullin P., Fennell D.A. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009, 14:986-994.
5. Zhou J. Multi-drug resistance in cancer 2010, Humana Press, New York. 1st ed.
6. Triller N., Korošec P., Kern I., Kosnik M., Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006, 54:235-240.
7. Stewart D.J. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010, 75:173-234.
8. Mano M.S., Rosa D.D., De Azambuja E., Ismael G.F., Durbecq V. The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treat Rev 2006, 33:64-77.
9. Dingemans A.M.C., Witlox M.A., Stallaert R.A., van der Valk P., Postmus P.E., Giaccone G. Expression of DNA topoisomerase IIα and toposiomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999, 5:2048-2058.
10. Di Leo A., Claudino W., Licitra S., Pestrin M., Larsimont D. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?. Eur J Cancer 2008, 44:2791-2798.
11. 4. Br J Cancer 1996, 74:1869-1876.
12. de Jong S., Zijlstra J.G., de Vries E.G.E., Mulder N.H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990, 50:304-309.
13. Schettino C., Bareschino M.A., Maione P., Rossi A., Ciardiello F., Gridelli C. The potential role of pharmacogenomic and genomic in the adjunivariate ant treatment of early stage non small cell lung cancer. Curr Genomics 2008, 9:252-262.
14. Ota S., Ishii G., Goto K., Kubota K., Kim Z.H., Kojika M., et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64:98-194.
15. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. For the IALT Bio Investigators, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjunivariate ant chemotherapy. N Engl J Med 2006, 355:983-991.
16. Hwang I.G., Ahn M.J., Park B.B., Ahn Z.C., Han J., Lee S., et al. ERCC1 expression as a prognostic marker in N2 (+) non small-cell lung cancer patients treated with platinum-based neoadjunivariate ant concurrent chemoradiotherapy. Cancer 2008, 113:1379-1386.
17. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25:2747-2754.
18. Zheng Z., Chen T., Li X., Haura E., Sharma A., Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007, 356:800-808.
19. Simon G., Sharma A., Li X., Hazelton T., Walsh F., Williams C., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:741-746.
20. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002, 8:2286-2291.
21. Wang L., Wei J., Qian X., Yin H., Zhao Y., Yu L., et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 2008, 8:97-103.
22. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T.J., et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005, 11:1534-1538.
23. Zhou W., Gurubhagavatula S., Liu G., Park S., Neuberg D.S., Wain J.C., et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004, 10:4939-4943.
24. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27:560-567.
25. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M., et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1194-1203.
26. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 14:1797-1803.
27. Niedernhofer L.J., Bhagwat N., Wood R.D. ERCC1 and non-small-cell lung cancer. N Engl J Med 2007, 14:2538-2540.
28. Bhagwat N.R., Roginskava V.Y., Acquafondata M.B., Dhir R., Wood R.D., Niedernhofer L.J. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009, 69:6831-6838.
29. Ushijima R., Takayama K., Izumi M., Harada T., Horiuchi Y., Uchino J., et al. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res 2007, 27:4351-4358.
30. Yeh J.J., Hsu N.Y., Hsu W.H., Tsai C.H., Lin C.C., Liang J.A. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein 1 and lung resistance-related protein expression in untreated small cell lung cancer. Lung 2005, 183:177-183.
31. Hsia T.C., Lin C.C., Wang J.J., Ho S.T., Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002, 180:173-179.
32. Kao A., Shiun S.C., Hsu N.Y., Sun S.S., Lee C.C., Lin C.C. Technetium-99m metoxyisobutylisonitrile chest imaging for small cell lung cancer. Ann Oncol 2001, 12:1561-1566.
33. Kawasaki M., Nakanishi Y., Kuwano K., Takayama K., Kiyohara C., Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 1998, 34:1352-1357.
34. Savaraj N., Wu C.J., Xu R., Lampidis T., Lai S., Donnelly E., et al. Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 1997, 20:398-403.
35. Holzmayer T.A., Hilsenbeck S., Von Hoff D.D., Roninson I.B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992, 84:1486-1491.
36. Sohn J.W., Lee S.J., Lee S.J., Kim E.J., Cha S.I., Kim C.H., et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006, 36:137-141.
37. Kim Y.H., Ishii G., Goto K., Ota S., Kubota K., Murata Y., et al. Expression of breast cancer resistance protein is associated with poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009, 65:105-111.
38. Sun Z., Chen J., Aakre J., Marks R.S., Garces Y.Y., Jiang R., et al. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Ann Oncol 2010, 21:2011-2016.
39. Lara P.N., Natale R., Crowley J., Lenz H.J., Redman M.W., Carleton J.E., et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
40. Yeh J.J., Hsu W.H., Huang W.T., Wang J.J., Ho S.T., Kao A. Technetium-99m tetrofosmin SPECT predicts chemotherapy response in small cell lung cancer. Tumor Biol 2003, 24:151-155.
41. Shiau Y.C., Tsai S.C., Wang J.J., Ho Y.J., Ho S.T., Kao C.H. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001, 169:181-188.
42. Ceppi P., Longo M., Volante M., Novello S., Cappia S., Bacillo E., et al. Excision repair cross complementing-1 and topoisomerase IIα gene expression in small-cell lung cancer patients treated with platinum and etoposide. J Thorac Oncol 2008, 3:583-589.
43. Lee H.W., Han J.H., Kim J.H., Lee M.H., Jeong S.H., Kang S.Y., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008, 59:95-104.
44. Batus M., Myint R., Coon J., Basu S., Kaiser K., Fidler M., et al. N-cadherin, E-cadherin, ERCC1, and c-kit expression in small cell lung cancer (SCLC) and potential for new therapeutic targets. J Clin Oncol 2009, 27(Suppl.). (Abstract 221579).
45. Hennemann M., Sostruznik M.H., Gaiger A.M., Barrios C.H. ERCC1 expression and survival in small cell lung cancer. J Clin Oncol 2009, 27(Suppl.). (Abstract 19080).
46. Skov B.G., Holm B., Erreboe A., Skov T., Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung. J Thorac Oncol 2010, 5:453-459.
47. Yu D., Zhang X., Liu J., Yuan P., Tan W., Guo Y., et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008, 14:2878-2886.